Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

• Published in: Journal of thoracic oncology Vol. 8; no. 7; pp. 823 - 859
• Main Authors: Lindeman, Neal I., Cagle, Philip T., Beasley, Mary Beth, Chitale, Dhananjay Arun, Dacic, Sanja, Giaccone, Giuseppe, Jenkins, Robert Brian, Kwiatkowski, David J., Saldivar, Juan-Sebastian, Squire, Jeremy, Thunnissen, Erik, Ladanyi, Marc
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2013; International Association for the Study of Lung Cancer
• Subjects: Anaplastic Lymphoma Kinase; Biomarkers, Tumor - genetics; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Evidence-Based Medicine; Expert Testimony; Gene Rearrangement; Genetic Testing; Humans; International Agencies; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Mutation - genetics; Patient Selection; Protein Kinase Inhibitors - therapeutic use; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor Protein-Tyrosine Kinases - genetics; Societies, Medical; Systematic Reviews as Topic

To establish evidence-based recommendations for the molecular analysis of lung cancers that are that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. Three cochairs without conflicts of inter...